Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection

Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional...

Full description

Bibliographic Details
Main Authors: Julia Schiffner, Insa Backhaus, Jens Rimmele, Sören Schulz, Till Möhlenkamp, Julia Maria Klemens, Dorinja Zapf, Werner Solbach, Alexander Mischnik
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Public Health
Subjects:
IgG
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2021.732787/full
id doaj-5541401c5b994dd3b6167a706c8a49d4
record_format Article
spelling doaj-5541401c5b994dd3b6167a706c8a49d42021-09-27T05:14:30ZengFrontiers Media S.A.Frontiers in Public Health2296-25652021-09-01910.3389/fpubh.2021.732787732787Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 InfectionJulia Schiffner0Julia Schiffner1Julia Schiffner2Insa Backhaus3Jens Rimmele4Sören Schulz5Till Möhlenkamp6Julia Maria Klemens7Dorinja Zapf8Werner Solbach9Werner Solbach10Werner Solbach11Alexander Mischnik12Center for Infection and Inflammation Research, University of Luebeck, Luebeck, GermanyGerman Center for Infection Research (DZIF), Standort Hamburg-Borstel-Luebeck-Riems, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyMedical Faculty, Centre for Health and Society, University Hospital, Institute of Medical Sociology, Heinrich-Heine-University, Düsseldorf, GermanyHealth Protection Authority, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyInstitute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, GermanyInstitute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, GermanyCenter for Infection and Inflammation Research, University of Luebeck, Luebeck, GermanyGerman Center for Infection Research (DZIF), Standort Hamburg-Borstel-Luebeck-Riems, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyHealth Protection Authority, Luebeck, GermanyCharacterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status.https://www.frontiersin.org/articles/10.3389/fpubh.2021.732787/fullCOVID-19SARS-CoV-2immunoglobulinIgGseroprevalenceinterferon-gamma release assay
collection DOAJ
language English
format Article
sources DOAJ
author Julia Schiffner
Julia Schiffner
Julia Schiffner
Insa Backhaus
Jens Rimmele
Sören Schulz
Till Möhlenkamp
Julia Maria Klemens
Dorinja Zapf
Werner Solbach
Werner Solbach
Werner Solbach
Alexander Mischnik
spellingShingle Julia Schiffner
Julia Schiffner
Julia Schiffner
Insa Backhaus
Jens Rimmele
Sören Schulz
Till Möhlenkamp
Julia Maria Klemens
Dorinja Zapf
Werner Solbach
Werner Solbach
Werner Solbach
Alexander Mischnik
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
Frontiers in Public Health
COVID-19
SARS-CoV-2
immunoglobulin
IgG
seroprevalence
interferon-gamma release assay
author_facet Julia Schiffner
Julia Schiffner
Julia Schiffner
Insa Backhaus
Jens Rimmele
Sören Schulz
Till Möhlenkamp
Julia Maria Klemens
Dorinja Zapf
Werner Solbach
Werner Solbach
Werner Solbach
Alexander Mischnik
author_sort Julia Schiffner
title Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
title_short Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
title_full Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
title_fullStr Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
title_full_unstemmed Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
title_sort long-term course of humoral and cellular immune responses in outpatients after sars-cov-2 infection
publisher Frontiers Media S.A.
series Frontiers in Public Health
issn 2296-2565
publishDate 2021-09-01
description Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status.
topic COVID-19
SARS-CoV-2
immunoglobulin
IgG
seroprevalence
interferon-gamma release assay
url https://www.frontiersin.org/articles/10.3389/fpubh.2021.732787/full
work_keys_str_mv AT juliaschiffner longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT juliaschiffner longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT juliaschiffner longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT insabackhaus longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT jensrimmele longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT sorenschulz longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT tillmohlenkamp longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT juliamariaklemens longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT dorinjazapf longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT wernersolbach longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT wernersolbach longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT wernersolbach longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
AT alexandermischnik longtermcourseofhumoralandcellularimmuneresponsesinoutpatientsaftersarscov2infection
_version_ 1716867159141908480